Ovarian tissue cryopreservation: Low usage rates and high live‐birth rate after transplantation
Open Access
- 8 October 2019
- journal article
- research article
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (2) , 213-221
Abstract
Introduction: The likelihood of survival after cancer treatment among young women with cancer has increased considerably, quality of life after treatment has drawn more attention. However, in young fertile women, fertility preservation is an important issue with regard to quality of life. One of the options of fertility preservation is ovarian tissue cryopreservation. The purpose of this follow‐up study is to present our clinical experiences and evaluate the long‐term follow up of ovarian cryopreservation to improve future patient selection.Material and methods: From July 2002 to December 2015 at the Leiden University Hospital, the Netherlands, 69 young women underwent ovarian tissue cryopreservation when they were at risk of iatrogenic premature ovarian insufficiency. Follow‐up data with regard to ovarian function were obtained until October 2018, from medical records and questionnaires.Results: Of the 69 women in whom ovarian tissue cryopreservation was performed, 12 died (15.9%), 57 were approached to participate, of which 6 were lost to follow up. The indications for ovarian tissue cryopreservation were malignant (81.1%) and benign (18.9%) diseases in which gonadotoxic treatment was scheduled. In total, twenty women (39.2%) are known to have premature ovarian insufficiency due to gonadotoxic treatment. Fifteen women conceived spontaneously, and delivered 25 babies. In this cohort, the usage rate of autotransplantation is 8.7% (7/69). In total, nine autotransplantations of cryopreserved ovarian tissue were performed in seven patients (of which 1 ovarian tissue cryopreservation was performed in another hospital) after which 6 babies were born to four women, giving a live‐birth rate of 57%.Conclusions: Ovarian tissue cryopreservation followed by autotransplantation is an effective method to restore fertility (live‐birth rate of 57%). The usage rate of 8.7% (6/69) indicates that more knowledge about the risk of premature ovarian insufficiency after gonadotoxic treatment is needed to be able to offer ovarian tissue cryopreservation more selectively.Keywords
This publication has 40 references indexed in Scilit:
- Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancerJournal of Assisted Reproduction and Genetics, 2012
- Genome-Wide Linkage in a Highly Consanguineous Pedigree Reveals Two Novel Loci on Chromosome 7 for Non-Syndromic Familial Premature Ovarian FailurePLOS ONE, 2012
- Toxicity of Chemotherapy and Radiation on Female ReproductionClinical Obstetrics & Gynecology, 2010
- Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile ageFertility and Sterility, 2010
- Oocyte cryopreservation: a feasible fertility preservation option for reproductive age cancer survivorsJournal of Assisted Reproduction and Genetics, 2010
- American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer PatientsJournal of Clinical Oncology, 2006
- Incidence, Time Course, and Determinants of Menstrual Bleeding After Breast Cancer Treatment: A Prospective StudyJournal of Clinical Oncology, 2006
- Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testingHuman Reproduction Update, 2005
- Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancerAnnals of Oncology, 2004
- Fertility preservation in female patientsHuman Reproduction Update, 2004